To understand the association of antidepressant-related weight gain with various aspects of worker productivity. METHODS: Employed individuals (Ն18 years of age) with diagnosed depression (excluding bipolar disorder) completed a web-based computer-generated 25-minute survey (study population identified by Harris Interactive). Weight gain was measured using the Toronto Side Effects Scale which measures medication-related side effects in the 2-weeks preceding the survey, and was analyzed as a 4-level ordinal variable (none, Ͻϭ2lbs, Ͻϭ4lbs, and Ͻϭ7lbs), where "none" was the referent category. The Work Productivity and Activity Impairment (WPAI) questionnaire was used to assess percent of impaired productivity (overall, absenteeism, presenteeism, activity impairment) during the 2-weeks preceding the survey, with higher numbers indicating greater impairment and less productivity (i.e., worse outcomes). Using distribution among current antidepressant users, each WPAI measure was categorized into quintiles, with the lowest and highest representing least and greatest impairment, respectively. Cumulative logit models were used to estimate the overall effect of weight gain on WPAI measures as well as across gender. RESULTS: Of the 1521 survey respondents, 872 (57%) reported current antidepressant use (60.6% female, mean age 49.9 Ϯ 13.5 years). Weight gain was associated with loss of productivity: Ͻϭ2lbs (odds ratio [OR]ϭ 1.54; pϭ0.005), Ͻϭ4lbs (ORϭ 2.14 ; pϭ0.0007 ) and Ͻϭ7lbs (ORϭ 2.96; pϭ 0.0009). In females, using "no weight gain" as a reference group, the odds of being in a worse overall productivity category increased with the increase of weight gain: Ͻϭ2lbs (odds ratio [OR]ϭ1.59; pϭ0.02), Ͻϭ4lbs (ORϭ2.17; pϭ0.005) and Ͻϭ7lbs (ORϭ3.13; pϭ0.01). Similar trends were observed in males: Ͻϭ2lbs (ORϭ1.43; pϭ0.15), Ͻϭ4lbs (ORϭ2.00; pϭ0.06) and Ͻϭ7lbs (ORϭ2.86; pϭ0.02). CONCLUSIONS: In employees with depression, antidepressant-related weight gain was associated with loss in overall productivity. Additional research to quantify the indirect costs of antidepressant-related weight gain in terms of productivity losses may be useful.
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PMH63 STAY HEALTHY THROUGH GAME-CARE THERAPEUTICS: IT'S TIME TO PLAY THE GAME! Aggarwal A Independent Research Consultant, Delhi, India OBJECTIVES: Health care research in present scenario is a platform wherein a range of interventions play their role to alleviate suffering and mitigate the course of diseases. Gaming console have so far demonstrated promising and considerable potential as rehabilitation and lifestyle treatments. The objective of this review was to study the advent and role of new generation gaming consoles (e.g. Nintendo Wii, Xbox, and PS3) in healthcare research in a systematic manner. METHODS: A consolidated search strategy was developed and run in EMBASE, MEDLINE, Cochrane, POPLINE, SCOPUS, and Clinicaltrials.gov databases to identify the trials utilising gaming consoles as principal intervention or supportive treatment in various disease areas. Grey literature was also identified though Google Scholar. Data extraction was performed and results were summarized. RESULTS: The data revealed that motion sensor and interactive gaming consoles have found their role in multiple health care fields ranging from rehabilitation, weight loss, stroke recovery, improvement in locomotor activity, Parkinson's disease, Alzheimer's disease, and back pain, etc. Also, their active presence in promoting exercise, health care coaching and monitoring, and health awareness programs has seen a marked increase due to new and innovative applications being identified every day. CONCLUSIONS: Newer health care technologies and platforms like gaming consoles help in numerous disease area to improve patient outcomes. Their transformation, propagation, and implementation as tools of healthcare services is a valuable strategy that the health care organizations should consider taking into consideration the emerging field of gaming technology in parallel with health technology. Detailed analysis, data tables, and graphs describing the study results will be presented.
PMH64 DIABETIC CARE AND RISK OF ACUTE COMPLICATIONS OF TYPE II DIABETICS WITH SCHIZOPHRENIA: A THREE-YEAR FOLLOW-UP OF HYPOGLYCEMIC THERAPY
Cheng JS 1 , Shih YT 2 1 Ghang Gung University, Taiwan, 2 National Health Research Institutes, Jhunan, Miaoli county, Taiwan OBJECTIVES: Individuals with schizophrenia are found to receive poorer medical care, and have a higher prevalence of diabetes than general population. Once a hypoglycemic therapy is needed, proper compliance to the therapy and diabetic care are important for achieving good glycemic control as well as preventing acute complications. Therefore, this study aimed to compare diabetic care and risk of acute complications after the initiation of the therapy for three years, between type II diabetics with schizophrenia versus those without schizophrenia. METHODS:
This study used the claims database of the National Health Insurance program. Enrollees who began oral hypoglycemic therapy in 2001, and had been diagnosed with schizophrenia and refilled at least one prescription of antipsychotic(s) in the year prior to the index date were included in the study (the case group). Enrollees without schizophrenia who began oral hypoglycemic therapy in 2001 were selected from a randomly selected sample of the enrollees to match the age and gender of the case group (1:1) (the comparison group). Indicators of diabetic care included good medication compliance (a medication possession ratioՆ0.8), blood glucose test, and HbA1c test. Indicators were measured annually. Acute complications were defined as emergency room visits or hospital admissions due to coma, hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Cox proportional hazards model was adopted to assess risk of acute complications. RESULTS: There were 544 subjects in the case group and comparison group, respectively. The percentage of subjects compliant to the therapy in the case group was decreasing. In addition, the case group had poorer blood glucose-related monitoring in the long run, and had a higher risk of acute complications than the comparison group. CONCLUSIONS: Diabetics with schizophrenia, compared with those without such a condition, had worse diabetic care. Better disease management will be necessary for this patient group.
PMH65 THE CHALLENGE OF ADHERENCE AND INDIVIDUALIZED TREATMENT IN SEVERE MENTAL DISORDERS -A NORDIC PERSPECTIVE
Granström O 1 , Dencker Vansvik E 2 1 AstraZeneca Nordic MC, Södertälje, Sweden, 2 AstraZeneca Nordic MC, Södertälje, Södertälje, Sweden OBJECTIVES: Drug choice and adherence are important aspects in schizophrenia and bipolar disorder (BD) and depend on patient and drug characteristics. Our aim was to examine Nordic psychiatrists' views on treatment choice, adherence, once daily dosing (ODD), and the use of extended release (XR) and instant release (IR) quetiapine. METHODS: We conducted a quantitative, telephone-based survey with 201 respondents randomly selected from a list of all 1906 Swedish and 677 Danish psychiatrists (excluding child and geriatric psychiatrists). Structured, one-hour qualitative interviews with 10 psychiatrists per country allowed us to further interpret the results. Data was collected by an independent research company. For binary variables, we performed a binomial test of the null hypothesis that the alternative responses were equally likely. RESULTS: One hundred one Danish and 100 Swedish psychiatrists were included; 65% were male and the mean (SD) psychiatric experience was 15.4 (8.2) years. No relevant country differences were found. 198 psychiatrists (99%) agreed on the importance of individualized treatment (pՅ0.0001). Respondents reported that 42% of schizophrenia and 33% of BD patients tried Ն3 antipsychotics before being stabilized. All respondents reported non-adherence to be common and all associated non-adherence with side-effects. 199 (99%) psychiatrists thought that ODD would improve adherence (pՅ0.0001), and 196 (98%) that it could mitigate partial adherence problems (pՅ0.0001). 179 respondents (89%) said that ODD reduces relapse rates (pՅ0.0001). A total of 147 psychiatrists (73%) associated quetiapine XR with less day sedation than IR (pՅ0.0001), and 132 (66%) associated XR with a reduced need for injection treatment (pՅ0.0001). In the qualitative interviews, XR was to a higher extent associated with antipsychotic monotherapy and IR more often with short-term use for e.g., sedation. CONCLUSIONS: Nordic psychiatrists considered individualized drug therapies in schizophrenia and BD to be important and perceived ODD to improve adherence. Respondents associated quetiapine XR with differential use compared to IR.
PMH66

12-YEAR TREND ANALYSIS ON THE CHARACTERISTICS, PRIMARY PAYER, AND PRESCRIBED MEDICATIONS OF PHYSICIAN-OFFICE VISITS FOR PATIENTS WITH DEMENTIA IN THE UNITED STATES
Chen YJ 1 , Sankaranarayanan J 2 , Murman DL 2 1 Covance Market Access Services, Gaithersburg, MD, USA, 2 University of Nebraska Medical Center, Omaha, NE, USA OBJECTIVES: This study was to estimate the national trend of physician-office visits for patients with Alzheimer's disease and senile dementia (ADϩSD), related characteristics, primary payment source, and prescribed medications over a period of 12 years (1998 -2009) in the United States. METHODS: Physician-office visits with ADϩSD diagnosis were identified in the National Ambulatory Medical Care Survey, stratified by time frame, to perform a trend analysis for patients aged 40ϩ with relevant ICD-9-CM codes (290.xx, 294.xx, 331.xx) . Main outcomes of interest are the changes in ADϩSD physician-office visits, primary payer source, and prescribed medications. A series of multivariate regressions (generalized linear model [GLM] with Poisson distribution) for number of medications prescribed per visit were employed by year to estimate the increased medication numbers associated with ADϩSD, controlling for patient demographics, comorbidities, and visit/payment characteristics. The impact of explanatory variables at both physician-office and visit level was also assessed through hierarchical modeling. RESULTS: Over the 12-year period, the annual ADϩSD visits and average all-purpose medications prescribed per ADϩSD visit have yearly growth rates of 18.2% and 10.7%, respectively. Medicare has consistently been the largest primary payer for ADϩSD physicianoffice visits (from 67% of visits in 1998 to 77% in 2009). Private payer and Medicaid also have increased shares (from 6% to 13% and from 4% to 5%, respectively) as primary payer, while fewer visit portions are primarily covered by Self-pay and Other sources. Numbers of drug mentions per visit attributable to ADϩSD, estimated through GLM regressions, are 0.64 in 1998, 1.92 in 2004, and 2.20 in 2009. CONCLUSIONS: ADϩSD patients' use of physician-office services has increased A298 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 -A 5 1 0
